Fresenius' Hits Akorn With Counterclaims Alleging Fraud
Fresenius Kabi AG responded to Akorn Pharmaceuticals Inc.'s lawsuit over their failed filed $4.75 billion merger in counterclaims filed Tuesday in Delaware Chancery Court, saying it discovered that Akorn had attempted...To view the full article, register now.
Already a subscriber? Click here to view full article